AMRX vs INVA
As of Sep 20, 2026, Amneal Pharmaceuticals (AMRX) scores 6.9/10 and Innoviva (INVA) 4.8/10 on AlphaStocks' five-model composite, so AMRX scores higher. AMRX trades 81% above its model fair value.
AMRX
Amneal Pharmaceuticals, Inc.
6.9
Consider Buy
$18.70
INVA
Innoviva, Inc.
4.8
Weak
$21.13
AMRX vs INVA: Which is the Better Investment?
Amneal Pharmaceuticals, Inc. (AMRX) scores 6.9/10 while Innoviva, Inc. (INVA) scores 4.8/10 on AlphaStocks' composite model. Amneal Pharmaceuticals, Inc. has the higher composite rating of Consider Buy. On a P/E basis, Innoviva, Inc. trades at 6.6x, making it the more attractively priced of the two.
This comparison is algorithmically generated and is not financial advice.
| Metric | AMRX | INVA |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 6.9/10▲ | 4.8/10 |
| Rating | Consider Buy▲ | Weak |
| Price | $18.70 | $21.13 |
| P/E Ratio | 84.3 | 6.6▲ |
| ROE | -80.0% | 24.8%▲ |
| Market Cap | $6B | $2B |
| Fair Value | $10.31 | — |
| Dividend Yield | — | — |
| Sector Rank | #16 of 168▲ | #118 of 168 |
| Model Verdicts | ||
| Piotroski | Strong▲ | Attractive |
| Buffett | Neutral | Attractive▲ |
| Graham | Neutral | Attractive▲ |
| Lynch | Attractive | Strong▲ |
| Greenblatt | Attractive | Strong▲ |
Related comparisons
AMRX vs INVA: Which Stock Scores Higher?
Amneal Pharmaceuticals, Inc. (AMRX) and Innoviva, Inc. (INVA) are both in the Health Care sector. AMRX currently leads with a composite score of 6.9/10 (Consider Buy) compared to INVA's 4.8/10 (Weak).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer